Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Raizada (Gainesville, United States of America). Oral presentation: Potential of ACE2 as a therapeutic target for pulmonary hypertension. Lung Science Conference 2010 - Biology of gene-environment interactions in the lung

Member's Comments

No comment yet.

Related content which might interest you: LSC 2010 Abstract: Potential of ACE2 as a therapeutic target for pulmonary hypertension Source: Annual Congress 2010 - New mechanisms in lung development, acute and chronic lung diseases Year: 2010 Pulmonary hypertension in ILDs: novel therapeutic data Source: International Congress 2019 – Lungs in the fog Year: 2019 Potential pharmacological interactions between oral pulmonary arterial hypertension (PAH) therapies and new oral anticoagulants Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012 Fibrocytes: potential new therapeutic targets for pulmonary hypertension? Source: Eur Respir J 2010; 36: 1232-1235 Year: 2010 Novel therapeutic perspectives in pulmonary arterial hypertension Source: Eur Respir J 2003; 22: 193-194 Year: 2003 Beta 3 adrenoceptor: a potential therapeutic target for pulmonary arterial hypertension Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020 Is inflammation a potential therapeutic target in chronic thromboembolic pulmonary hypertension? Source: Eur Respir J 2014; 44: 842-845 Year: 2014 Targeting HIF2a-ARNT hetero-dimerisation as a novel therapeutic strategy for pulmonary arterial hypertension Source: Eur Respir J, 57 (3) 1902061; 10.1183/13993003.02061-2019 Year: 2021 Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension Source: Eur Respir J 2010; 36: 808-818 Year: 2010 Lung transplantation for pulmonary hypertension: the impact of new drug therapies Source: Annual Congress 2004 - Lung transplantation: new insights in advanced lung disease and new drug developments - do they impact on selection criteria? Year: 2004 Adherence to pulmonary arterial hypertension targeted therapies Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 PSGR olfactory receptor: A new potential target in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 Oral delivery of transplastomic plant derived angiotensin converting enzyme2 - a novel approach for pulmonary hypertension therapeutics Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options Source: Eur Respir Rev 2009; 18: 24-28 Year: 2009 Outcomes from use of targeted therapy in pulmonary hypertension associated with sarcoidosis (PHAS) Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 Role of microRNA 17/92 cluster and microRNA 21 in the pathogenesis of pulmonary hypertension – Novel therapeutic targets Source: Annual Congress 2013 –Pulmonary circulation: basic science Year: 2013 A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension Source: Eur Respir J, 51 (6) 1702638; 10.1183/13993003.02638-2017 Year: 2018 RESPITE: Riociguat in pulmonary arterial hypertension patients with an inadequate response to phosphodiesterase type 5 inhibitors Source: International Congress 2016 – Clinic of pulmonary hypertension Year: 2016 Subcutaneous treprostinil: a new therapeutic approach for idiopathic paediatric pulmonary hypertension Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009